Then you have the fact that clinical trials often underrepresent minorities. This can lead to skewed AI models, with 80 percent of trials facing recruitment delays due to these issues. Given that ...

Regulatory deregulation and liquid biopsy adoption pushing the rapid growth of the oncology companion diagnostic market. In ...

The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

In the past year, OncoHost has continued to strengthen PROphet®'s biological explainability and clinical relevance, including ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier stage diagnosis. States adopting Medicaid expansion saw improved survival ...